Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Multi-medicine medicine-resistant RNA interference medicine for resisting tumor

A technology of RNA interference and multi-drug resistance, applied in the direction of anti-tumor drugs, DNA/RNA fragments, drug combinations, etc., can solve problems such as adverse reactions, high toxicity, and limited clinical application

Inactive Publication Date: 2004-02-25
INST OF HEMATOLOGY & BLOOD HOSPITAL CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, dozens of drugs that can reverse MDR have been reported, but the toxicity of the effective drug concentration is high, causing serious adverse reactions, which limits its clinical application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Multi-medicine medicine-resistant RNA interference medicine for resisting tumor
  • Multi-medicine medicine-resistant RNA interference medicine for resisting tumor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] After K562 / A02 cells were treated with siRNA for 24 hours, the expression of mRNA in the si-mdr1 group was down-regulated by (17.23±2.47)% (p>0.05) compared with the negative control group, and mdr- 1 mRNA expression was significantly reduced, respectively (38±1.23)% and (58±1.54)% (pfigure 1 .

Embodiment 2

[0048] Example 2. P-gp expression detection

[0049] After 48 hours of siRNA action, flow cytometry showed that the three groups inhibited the expression of p170 to varying degrees, and the positive rate of p170 expression in the si-mdr1 action group decreased from (76.0±1.03)% before treatment to (56.72±1.03)% after treatment. 1.41)%, the si-mdr2 effect group decreased to (42.70±1.17)% (p0.05), see figure 2 .

[0050] Changes in drug sensitivity of K562 / A02 cells after RNAi treatment: IC 50 Refers to the concentration of chemotherapeutic drugs when the cell inhibition rate is 50%. It can be seen from Table 1 that after the action of si-mdr2 and si-mdr3, the sensitivity of K562 / A02 to the chemotherapeutic drug ADM increases, suggesting that RNAi can restore the sensitivity of K562 / A02 to chemotherapeutic drugs. sensitivity. Example 3. Reversal effect of siRNA on drug resistance of K562 / A02 cells

Embodiment 3

[0050] Changes in drug sensitivity of K562 / A02 cells after RNAi treatment: IC 50 Refers to the concentration of chemotherapeutic drugs when the cell inhibition rate is 50%. It can be seen from Table 1 that after the action of si-mdr2 and si-mdr3, the sensitivity of K562 / A02 to the chemotherapeutic drug ADM increases, suggesting that RNAi can restore the sensitivity of K562 / A02 to chemotherapeutic drugs. sensitivity. Example 3. Reversal effect of siRNA on drug resistance of K562 / A02 cells

[0051] Table 1 compares the results of siRNA reversal of drug resistance in K562 / A02 cells. Each experiment was repeated 3 times, with 3 parallel wells each time, and the average value was taken. si-mdr1, si-mdr2 and si-mdr3 all have multidrug resistance reversing effects, and si-mdr3 has the most significant effect.

[0052] Table 1

[0053] IC 50 (μg / ml) relative reversal efficiency

[0054] (%)

[0055] K562 0.05 /

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses an antitumor multi-drug drug-resistant RNA interference drug, provides a group of nucleotide sequences of interference RNA of therapeutic drug pointed at drug-resistant gene mdr-1 and P-glycoprotein (P-gp) expression and function for resisting leucosis and other tumor. It has the target antitumor cell multidrug drug-resistant (mdr-1) gene and P-glycoprotein (P-gp) expression and function. It raises the sensitivity of leucosis cell conventional chemical therapeutic drug and enhances the action of chemical therapeutic drug for killing malignant tumor cell of hemopoietic system.

Description

technical field [0001] The invention relates to anti-tumor drugs, especially anti-tumor multidrug-resistant RNA interference drugs. Background technique [0002] Multidrug resistance (MDR) is an important obstacle to long-term remission of leukemia and other malignant tumors with conventional chemotherapy. Studies have shown that the overexpression of p-glycoprotein (p-glycoprotein, P-gp) encoded by the mdr-1 gene on the surface of tumor cells is the main mechanism leading to multidrug resistance of tumor cells, and it is also a good target for reversing drug resistance. At present, dozens of drugs that can reverse MDR have been reported, but the toxicity of the effective drug concentration is high, causing serious adverse reactions, which limits its clinical application. Therefore, targeted therapy targeting the mdr-1 gene and its protein is a hot spot in research on the reversal of leukemia multidrug resistance at home and abroad. [0003] RNA interference (RNA interfere...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61P35/00C12N15/113
CPCC12N2310/14C12N15/1138C12N2320/31A61P35/00
Inventor 韩忠朝彭智
Owner INST OF HEMATOLOGY & BLOOD HOSPITAL CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com